PO.IM02.01 · 免疫学
肺部炎症在致癌性KRAS驱动的肺腺癌小鼠模型中加速肿瘤进展
Lung inflammation accelerates tumor progression in a mouse model of oncogenic KRAS driven lung adenocarcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
近期对包括肺在内的多个器官的人体组织样本研究表明,典型致癌突变的出现率高于与这些组织相关癌症的已知发病率。其他工作已将多种炎性疾病与相关器官癌症发病率的升高联系起来。就肺腺癌(LUAD)而言,炎性肺疾病可能为肿瘤的生长创造有利环境,而阐明其发生机制可能揭示LUAD预防的途径。我们使用一种转基因小鼠模型,通过向肺内递送表达Cre的病毒,在正常II型肺泡细胞中诱导致癌性KRAS及荧光团tdTomato的表达来启动LUAD,我们证明多种炎症刺激加速了早期肿瘤生长。在这些荷瘤小鼠中模拟特发性肺纤维化以及细菌或病毒性肺感染,尽管通过流式细胞术、RNA测序和ELISA所表征的肺免疫细胞群和信号因子受到诸多不同的影响,但每种模型在肿瘤进展的早期和晚期时间点均导致平均肿瘤体积和总肿瘤负荷的增加。对早期病灶的免疫荧光染色使我们能够定量炎症条件下病灶体积的增大,并研究免疫细胞与这些小病灶的关联,揭示在所有炎症条件下KI-67+ F4/80+巨噬细胞在病灶附近的密度均增加。我们正积极致力于揭示免疫细胞群与早期癌细胞之间导致该条件下肿瘤生长加速的通讯节点。我们观察到,在我们的LUAD小鼠模型中,暴露于肺部炎症会加速肿瘤生长;通过表征炎性免疫微环境以及炎症期间介导加速生长的免疫细胞与癌细胞之间的通讯,本项目旨在识别LUAD预防的分子靶点。
查看英文原文 English abstract
Recent studies of human tissue samples in various organs including the lung have revealed the presence of canonical oncogenic mutations at rates higher than known incidence rates of cancers associated with these tissues. Other work has linked diverse inflammatory diseases to increased incidence rates of cancers associated with the involved organs. In the context of lung adenocarcinoma (LUAD), inflammatory lung diseases may produce a favorable environment for the outgrowth of tumors, and characterizing how this may occur could uncover avenues for LUAD prevention. Using a transgenic mouse model where LUAD is initiated by inducing expression of oncogenic KRAS and the fluorophore tdTomato in normal alveolar type II cells via delivery of Cre-expressing virus into the lung, we demonstrated that a range of inflammatory insults accelerated early tumor growth. Modelling of idiopathic pulmonary fibrosis and bacterial or viral lung infections in these tumor bearing mice each resulted in an increase in average tumor size and total tumor burden at both early and late timepoints of tumor progression, despite showing many divergent impacts on lung immune populations and signaling factors as characterized through flow cytometry, RNA sequencing, and ELISAs. Immunofluorescence staining of early lesions allowed us to quantify the increase in lesion size under inflammatory conditions and to investigate the association of immune cells with these small lesions, revealing that KI-67+ F4/80+ macrophages showed increased density proximal to lesions under all inflammatory conditions. We are actively working to uncover the points of communication between immune populations and early cancer cells that result in this accelerated tumor growth under these conditions. We have observed that in our LUAD mouse model tumor growth is accelerated by exposure to lung inflammation, and through characterization of the inflamed immune microenvironment and communication between immune and cancer cells during inflammation that mediate accelerated growth, this project aims to identify molecular targets for LUAD prevention.
利益披露 Disclosure
S. A. Nelson, None..
J. Kassama, None..
C. M. Cabana, None..
A. M. Jefferson, None.
T. E. Jacks,
Amgen g., Board of Directors, non-salaried role).
Thermo Fisher Scientific g., Board of Directors, non-salaried role).
Dragonfly Therapeutics Other, Co-Founder and Scientific Advisory Board member.
SQZ Biotech Other, Scientific Advisory Board member.
Skyhawk Therapeutics Other, Scientific Advisory Board member.